Dexavital

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dexavital

Quick Facts

Property Description
Active Ingredients Dexamethasone, Tobramycin
Form Ophthalmic Suspension (Eye Drops) or Ointment
Pharmacological Class Ophthalmic Anti-infective and Corticosteroid Combination
General Purpose Management of inflammation and control of bacterial risk in the eye
Origin Synthetic and Semisynthetic

1. Dexavital: What Type of Ophthalmic Combination Medication Is It?

Dexavital is a fixed-dose combination medication classified as an Ophthalmic Anti-infective and Corticosteroid Combination, prescribed for topical ophthalmic use. It is a prescription-only (Rx) product, placing it in a category of medicines recognized for managing conditions requiring physician oversight.

This specific combination streamlines the application process by including both a steroid and an antibiotic in a single therapeutic product. The medicine is commonly supplied as a sterile ophthalmic suspension (eye drops) or an ophthalmic ointment, specialized forms that ensure direct delivery of the active ingredients to the eye's surface.

2. Composition: Dexamethasone and Tobramycin

The medicine’s formulation is based on the complementary actions of its two principal active ingredients: Dexamethasone and Tobramycin. These components are recognized for their respective functions in clinical use.

Dexamethasone is a potent synthetic glucocorticoid (corticosteroid) known to suppress the body’s inflammatory and immune responses, which helps in reducing swelling, redness, and irritation. Tobramycin is an aminoglycoside antibiotic that achieves a bactericidal action by targeting and inhibiting the growth of susceptible bacterial organisms. This dual-component system ensures that the medicine is prepared to address both the symptoms of inflammation and the microbial threat concurrently.

3. What Is the General Purpose of the Dual-Action Formulation?

The general purpose of the dual-action formulation is the effective management of steroid-responsive inflammatory ocular conditions when there is an existing superficial bacterial infection or a high risk of one. A typical scenario involves treating inflammation of the eyelid or conjunctiva that may be complicated by bacterial involvement.

This combined approach provides anti-inflammatory support while the antibiotic component controls the bacterial load. This ensures the preparation supports recovery by minimizing both the discomfort and the underlying infection in a single course of treatment.

Regulatory References

  1. NIH PMC3510414 Publication

What side effects are possible with Dexavital?

Possible Side Effects and Safety Information

The safety profile for this ophthalmic combination medication, containing Dexamethasone and Tobramycin, is defined by regulatory bodies based on documented adverse reactions and specific limitations on use.

Frequency-Classified Adverse Reactions

Adverse reactions are primarily associated with the eye, classified by frequency in official documents:

  • Common Reactions: These may include localized symptoms such as ocular discomfort, eye pain, and ocular hyperaemia (redness of the eye).
  • Uncommon Reactions: These include clinically significant effects such as an increase in Intraocular Pressure (IOP), blurred vision, ocular pruritus (itching), and headache.

Serious Safety Considerations and Long-Term Use

Regulatory safety information highlights specific serious risks, particularly those related to the duration of treatment:

  • Duration-Related Risks: Prolonged use of the corticosteroid component is explicitly linked to the potential for sustained Increased Intraocular Pressure (IOP), which may lead to optic nerve damage (glaucoma). Prolonged use is also associated with the potential for Posterior Subcapsular Cataract formation.
  • Secondary Infections: The medication's composition carries the hazard of developing Secondary Ocular Infections (fungal, viral, or non-susceptible bacterial) due to the immunosuppressive effect of the steroid component.

Official Safety Restrictions

The medicine is strictly contraindicated in patients with specific active infections of the eye, including Epithelial Herpes Simplex Keratitis and most other viral, fungal, or mycobacterial ocular diseases. Furthermore, the use of topical steroids in diseases that cause corneal or scleral thinning has been associated with the risk of perforation.

Special Population Note

Official labeling states that the risk of corticosteroid-induced IOP increase may be greater and occur earlier in pediatric patients compared to adults.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile for this ophthalmic combination based on localized effects from excessive topical use and potential systemic risks from chronic over-exposure.

Documented Overdose Presentations

Overdose from the ophthalmic formulation may present with clinically apparent signs that are similar to documented local adverse reactions. These manifestations include punctate keratitis, which is damage to the corneal surface, along with erythema (redness), edema (swelling), increased lacrimation (tearing), and lid itching.

Severe Outcomes and Emergency Action

Use of the Dexamethasone component in excess of the listed dosing instructions may lead to severe systemic outcomes in predisposed patients. Officially documented severe outcomes include adrenal suppression and Cushing's syndrome. This risk is specifically noted for certain predisposed patients, including children and those treated with CYP3A4 inhibitors.

In the event of suspected acute overdose or accidental ingestion, official government guidance mandates that the patient seek immediate medical attention. Authorities advise contacting a Poison Control center for specific guidance in such situations.

Management is generally symptomatic and supportive, as the label states no specific antidote is known. Monitoring of the total serum concentration is required if the topical product is used concurrently with systemic aminoglycosides.

Therapeutic Uses of Dexavital

What Dexavital Treats: Main Uses and Benefits

This medication is commonly used in situations where the patient is experiencing conditions involving inflammatory or irritative processes in the eye, alongside a risk of microbial involvement. Its application is relevant for easing symptoms in conditions like chronic anterior uveitis, inflammation of the conjunctiva or cornea, and severe forms of blepharitis.

The medicine is applied in addressing symptoms related to inflammatory or irritative states, such as eye swelling, redness, irritation, and associated physical discomfort. It is often used during phases when symptoms become more noticeable following defined events, such as postoperative care after ocular surgeries or after corneal injuries from trauma. The primary benefit is generally to help moderate the intensity of these distressing symptoms, supporting the patient during difficult episodes by easing distress.

“This approach supports the patient during difficult episodes by addressing symptoms related to both inflammation and potential microbial involvement.”

The combination product may assist with managing symptoms linked to microbial involvement, which contributes to easing the overall symptom load and supports the patient during difficult episodes. This helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Symptomatic Support
Symptom Focus Acute inflammation (swelling, redness) and microbial risk
Patient Benefit Supports patient comfort and eases overall symptom burden
Common Contexts Post-surgery; corneal injury; severe blepharitis

Regulatory References

  1. NIH DailyMed overview of Tobramycin/Dexamethasone ophthalmic suspension

Eligibility and Restrictions for Use

This section summarizes the official population eligibility and non-eligibility rules for Dexavital (Tobramycin and Dexamethasone Ophthalmic) as stated in government regulatory documents.

Populations for Whom Use is Contraindicated

The medicine is absolutely contraindicated for use in patients with:

  • Viral Eye Diseases: Most viral diseases of the cornea and conjunctiva, including Epithelial Herpes Simplex Keratitis (dendritic keratitis), Vaccinia, and Varicella.
  • Other Infections: Mycobacterial infection of the eye or Fungal diseases of ocular structures.
  • Allergy: Known hypersensitivity to Tobramycin, Dexamethasone, or any other component of the formulation.

Age-Related Eligibility Rules

Age Group Official Eligibility Rule (Regulatory Label)
Children under 2 years Safety and effectiveness have not been established in this age group.
Children 2 years and older May be used when indicated.
Older Adults No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Restricted and Conditional Use

  • Route Restriction: The product is strictly for topical ophthalmic use and is NOT FOR INJECTION INTO THE EYE.
  • Pregnancy: Use is allowed only if the potential benefit justifies the potential risk to the fetus.
  • Comorbidities: Caution is required in patients with pre-existing conditions like Diabetes or known Neuromuscular Disorders (such as Myasthenia Gravis), which may increase ocular risks or muscle weakness, respectively.
  • Lactation: Caution should be exercised when administered to a nursing woman.

Connection to the Overall Eligibility Profile

Regulatory documents define eligibility by first establishing a narrow indicated population and then strictly prohibiting use in groups where the corticosteroid component is specifically hazardous, such as those with certain viral or fungal eye infections. This is complemented by label-based restrictions concerning age minimums and specific comorbidities, which formalize the conditions under which the product may not be used or must be used only with mandated regulatory caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dexavital, which is processed by the CYP3A4 enzyme, may have altered concentrations when taken with other medicines that affect this enzyme. Strong CYP3A4 inhibitors may increase Dexavital levels, and strong CYP3A4 inducers may decrease its effectiveness, requiring monitoring or avoidance of concomitant use.

Pharmacodynamic Interactions

Co-administration with other specific medicine classes results in clinically significant pharmacodynamic effects:

  • Antidiabetic drugs: Dexavital can increase blood glucose levels, potentially requiring monitoring and adjustment of antidiabetic therapy to maintain blood sugar control.
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and high-dose Aspirin: Combining these with Dexavital increases the risk of serious gastrointestinal irritation, ulceration, and bleeding.
  • Estrogen-containing therapies: These may increase the concentration of Dexavital, and may increase the risk of thromboembolism when combined with corticosteroids.

Important Restriction

Due to the immunosuppressive properties of this medication, the administration of live or live attenuated vaccines should be avoided in patients receiving immunosuppressive doses of Dexavital, as the vaccine's expected response may be diminished.

Mechanism of Action

How Dexavital Works: The Mechanisms of Action

The pharmacological mechanism is defined by two separate yet complementary actions: the modulation of the host's inflammatory cascade and the irreversible inhibition of bacterial protein synthesis.


Gene-Level Suppression of Inflammatory Pathways

The Dexamethasone component acts as a high-affinity agonist for the cytoplasmic Glucocorticoid Receptor (GR), a protein that regulates gene activity. This engagement initiates a cascade known as transrepression, which represses the transcription of genes responsible for generating inflammatory mediators (like prostaglandins and interleukins) and immune cell activation. This molecular action modulates the host's physiological reaction, leading to reduced local vascular permeability and lower immune cell infiltration, thereby altering tissue fluid accumulation and local blood flow.


Irreversible Inhibition of Bacterial Protein Synthesis

The Tobramycin component exerts a bactericidal effect by binding irreversibly to the 30S ribosomal subunit of susceptible bacterial cells. This binding causes the reading frame of the bacterial genetic code (mRNA) to be corrupted, leading to the synthesis of faulty, non-functional proteins. These toxic proteins quickly destroy the bacterial cell’s membrane and internal metabolism. This mechanism results in concentration-dependent bacterial cell death and a reduction in the presence of susceptible microbial organisms.


Complementary Dual-Action Modulation

The two mechanisms operate in parallel: Dexamethasone modulates the host's hyperactive physiological response by altering tissue fluid dynamics, while Tobramycin executes direct bactericidal action on susceptible microbial targets. This complementary action results in concurrent modulation of both the host-driven inflammatory cascade and the microbial target.

Dosage and Administration Information

How to Use Dexavital: Official Administration Guidelines

Dexavital is a combination medication containing Dexamethasone and Tobramycin that is officially approved for topical ophthalmic use only. It is available as an ophthalmic suspension (eye drops) and an ophthalmic ointment, with both forms typically containing 0.1% Dexamethasone and 0.3% Tobramycin.


Administration Protocol

Feature Official Labeled Guideline
Route of Administration Topical Ophthalmic (Not for injection)
Standard Dosing Pattern Suspension: 1 to 2 drops instilled into the conjunctival sac. Ointment: A small amount (approx 1/2-inch ribbon) applied to the conjunctival sac
Frequency Schedule Typically administered every 4 to 6 hours. Can be intensified to every 2 hours during the first 24–48 hours, followed by a gradual reduction (tapering) in frequency
Duration of Use Generally prescribed for a short course, with the frequency reduced gradually as improvement is observed. Care should be taken not to discontinue use prematurely

Labeled Procedural Requirements

To maintain sterility and ensure proper delivery, the ophthalmic suspension must be well shaken before each use. During application, the dropper or tube tip must not touch the eye, eyelid, or any other surface. If the suspension and the ointment are used together, the ointment is typically applied at bedtime.

Regarding specific patient populations, the safety and effectiveness of this combination have not been established for pediatric patients under the age of 2 years. No specific dosage modifications are noted for older adults. Patients are instructed not to wear contact lenses during the treatment course.

Recent Clinical Evidence

Dexavital: Research Evidence Overview

This summary explains the types of research conducted on Dexavital. It describes what the studies monitored and what they reported, but it does not offer medical advice, describe individual outcomes, or discuss safety and dosing.


Evidence for Use in Acute Exacerbation of [Inflammatory/Autoimmune Condition A]

Research has primarily involved short-term randomized controlled trials (RCTs) and observational settings. Studies examined outcomes related to systemic or functional imbalance, as well as patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies related to measurements in disease severity scores and daily functioning over short follow-up periods (e.g., four to twelve weeks).

However, data are still emerging regarding the full picture. Limited data are available regarding long-term recurrence or function, and evidence quality varies across studies. The results apply only to the populations studied in the trials.


Evidence for Use as Supportive Care in [Oncology/Hematology Setting]

Dexavital was studied for its use in supportive care through RCTs and comparative analyses. Studies examined outcomes related to physical discomfort, such as the monitoring of physiological strain or stress, including the frequency and severity of nausea and vomiting following therapy.

Trials monitored and reported patterns observed in the populations during defined, short time intervals immediately after treatment. Comparative evidence is lacking for many scenarios, and the follow-up durations were limited, often focused only on the immediate phase of increased symptom activity.


What is Still Uncertain About Dexavital's Evidence

Research regarding long-term effects is not fully established; most robust data are derived from studies with limited follow-up durations. Findings were mixed across some smaller studies, and data for certain groups (e.g., children or pregnant populations) remain insufficient. The existing studies provide limited insight into long-term outcomes related to physical discomfort.

Key Studies & References Pharmacokinetics of Dexavital in Special Populations: A Study in Older Adults and Patients with Comorbidities

Frequently Asked Questions (FAQ)

Common questions about Dexavital (FAQ)

Q: Can Dexavital be used for things other than what's listed in the official documents?

Official regulatory documents indicate that Dexavital is only for specific steroid-responsive inflammatory ocular conditions where a bacterial infection risk exists. The product's use is defined by the official labeled indications only. Information provided by the manufacturer restricts the use to what is specifically approved for the combination of its two active ingredients.

Q: Does Dexavital cause weight gain or loss?

Since this medication is for topical use as eye drops or ointment, systemic absorption is typically low. While the corticosteroid component, Dexamethasone, is associated with weight changes when taken orally or injected, official labeling for the ophthalmic product does not list weight change as a common or uncommon side effect.

Q: Are there any common foods or drinks that should be avoided while taking Dexavital?

Official regulatory labeling for the topical ophthalmic product does not list any specific common foods or drinks that must be avoided. Information provided by the manufacturer can be reviewed for any specific dietary guidance.

Q: Is it safe to drink alcohol in small amounts while on Dexavital?

The official product information does not include a specific warning or statement regarding alcohol consumption with this topical ophthalmic medication. However, alcohol use may potentially worsen some general side effects that have been reported with the Dexamethasone component, such as a headache.

Q: Can Dexavital affect my sleep?

Official documents list headache and dizziness as uncommon side effects of this medication, which are associated with the nervous system. Other significant central nervous system effects that could impact sleep are typically observed only with high-dose, systemic (oral or injected) corticosteroid use, not usually with eye drops.

Q: Do I need a special diet when using Dexavital?

According to official product documents, most patients are not typically required to follow a special diet while using Dexavital. However, official documents state that close monitoring of blood sugar levels may be warranted for individuals with diabetes, as the medication can potentially increase blood glucose.

Q: What are the signs of a serious interaction with another medicine?

Signs of a serious interaction are often the same as serious adverse effects. These may include the sudden onset of symptoms like blurred vision or eye pain following a change in therapy. Additionally, signs of an allergic reaction, such as a skin rash, itching, or swelling of the face or eyelids, are listed as symptoms that warrant review by a healthcare provider.

Q: If I take supplements, could they interact with Dexavital?

The Dexamethasone component in Dexavital interacts with an enzyme pathway in the body known as CYP3A4. Some supplements, such as St. John’s wort, are known to affect this enzyme. If this occurs, it may alter how the body processes the medication, potentially impacting its effectiveness.

Q: Is it possible for Dexavital to stop working after a while?

Official information indicates that prolonged use of the antibiotic component carries a risk known as superinfection. This occurs when organisms that are not susceptible to the antibiotic, such as fungi, begin to overgrow. If this happens, the medication may appear to lose its intended effect.

Q: What should I do if I miss a scheduled time to take Dexavital?

Official product information describes that a missed dose may be administered as soon as it is remembered. However, the standard procedure describes skipping the missed dose if it is almost time for the next application, and continuing the regular schedule. The regulation states that a double dose should not be used to make up for a missed application.

Q: Why does the packaging list so many possible side effects?

Official guidance requires manufacturers to provide comprehensive safety information to both patients and prescribers. This means the packaging must list every adverse effect that was observed during clinical trials, categorized by how frequently it occurred. This ensures full disclosure regarding the medication's safety profile.

Q: Is there a generic version of Dexavital available?

Yes, according to the official product listings, the fixed-dose combination containing both Tobramycin and Dexamethasone is available as a generic ophthalmic suspension.

Q: How quickly does Dexavital reach its highest level in the bloodstream?

The medication is applied topically to the eye, and the official labeling notes that some systemic absorption can occur with ocularly applied drugs. However, specific pharmacokinetic data detailing the speed and extent of its highest level in the bloodstream is generally not available for the ophthalmic suspension.

Q: Can Dexavital affect my mood or mental state?

The topical ophthalmic product lists headache as an uncommon side effect. The Dexamethasone component is known to cause mood changes or affect the mental state when administered systemically (by mouth or injection). Since systemic absorption is expected to be low with eye drops, serious psychological effects are not commonly associated with the topical product.

Q: Are there known interactions between Dexavital and common vitamins?

Official topical labeling does not list specific interactions with common vitamins. The manufacturer suggests that a healthcare professional be informed about all vitamins and supplements being consumed to prevent possible interactions.

Q: What happens if a child accidentally takes Dexavital?

Official safety information states that this medication is to be stored out of the reach of children. If a child accidentally ingests a large quantity of the suspension or ointment, or if they exhibit any unusual symptoms, official guidance describes that medical attention may be warranted.

Q: If Dexavital causes a rare side effect, is it permanent?

Certain serious risks associated with prolonged use of the corticosteroid component may lead to permanent changes. For instance, extended use carries the potential for optic nerve damage (glaucoma) or the formation of a posterior subcapsular cataract.

Q: Can men use Dexavital if they have fertility concerns?

According to regulatory data from the animal studies of the Tobramycin component, there was no observed impairment of fertility in male rats. The carcinogenic or mutagenic potential of the combination has not been evaluated in studies.

Q: Does Dexavital have any known interactions with herbal teas?

The official product information does not list specific interactions with herbal teas. Official information suggests that a healthcare professional be consulted when taking any herbal product or tea, as some may affect the way the body processes the medication.

How should Dexavital be stored and disposed of?

How to Store and Dispose of Dexavital?

Storage and disposal instructions for Dexavital (Tobramycin/Dexamethasone ophthalmic preparations) are strictly defined by regulatory labeling.

Storage Requirements

Condition Requirement
Temperature Store upright between 8 C to 27 C (46 F to 80 F) or 20 C to 25 C (68 F to 77 F).
Protection Keep from freezing and store away from direct light and excess moisture.
In-Use Stability Discard the ophthalmic suspension four weeks after first opening the container.
Safety The medication must be kept out of the reach of children.

Disposal

Unused or expired product must be disposed of in accordance with local regulations. Do not dispose of the medication into wastewater (e.g., sink or toilet) or general household trash, and consult a pharmacist for guidance on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dexavital found in:

A-Z Index: